scispace - formally typeset
Search or ask a question

Showing papers in "Vaccine in 2011"


Journal ArticleDOI
02 Sep 2011-Vaccine
TL;DR: Both the degree of threat experienced in the 2009 pandemic influenza outbreak and perceptions of vaccination as an effective coping strategy were associated with stronger intentions and higher uptake of vaccination, finding interventions to increase seasonal influenza vaccination in advance of a future pandemic may be an effective strategy.

523 citations



Journal ArticleDOI
12 Apr 2011-Vaccine
TL;DR: The nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants are described and those agents for which clinical results are available are reviewed.

442 citations


Journal ArticleDOI
29 Jan 2011-Vaccine
TL;DR: Among insured women, aged 19-26 years, those who discussed the HPV vaccine with their physician and received a recommendation were overwhelmingly more likely to be vaccinated.

428 citations


Journal ArticleDOI
16 Mar 2011-Vaccine
TL;DR: AS03's promotion of monocytes as the principal antigen-presenting cells, and its effects on granulocytes and cytokines, may all contribute to enhancing the antigen-specific adaptive immune response.

392 citations


Journal ArticleDOI
17 Feb 2011-Vaccine
TL;DR: It is shown that all recruited cell types take up both adjuvant and antigen to transport them to the draining lymph nodes (LNs), and compared to alum, MF59-injection lead to a more prominent neutrophil recruitment and a more efficient antigen re-localization from the injection site to the LN.

372 citations


Journal ArticleDOI
26 Oct 2011-Vaccine
TL;DR: Multiple reasons for under- vaccination and non-vaccination were identified, indicating that a multi-faceted approach is needed to reach under-vaccinated and unvaccinated children.

344 citations


Journal ArticleDOI
23 Sep 2011-Vaccine
TL;DR: The different steps and challenges of developing CYD TDV are discussed, from research to industrialization, and some of the challenges to the successful introduction of a dengue vaccine into immunization programs are summarized.

302 citations


Journal ArticleDOI
02 Sep 2011-Vaccine
TL;DR: The revised survey is a valid and reliable instrument to identify vaccine-hesitant parents and Cronbach's α coefficients for the 3 sub-domain scales created by grouping the remaining 15 items were .74, .84, and .75, respectively.

274 citations


Journal ArticleDOI
18 Apr 2011-Vaccine
TL;DR: Pneumococcal disease remains a substantial cause of morbidity and mortality even in the era of routine pediatric and adult vaccination, and the cost of pneumococcal Disease among younger working adults (18-<50) nearly equaled those ≥ 65.

267 citations


Journal ArticleDOI
18 Jul 2011-Vaccine
TL;DR: Data from Ad5, Ad26, Ad35, and Ad48 NAb titers in 4381 individuals from North America, South America, sub-Saharan Africa, and Southeast Asia are reported to inform the clinical development of alternative serotype rAd vaccine vectors in the developing world.

Journal ArticleDOI
05 Apr 2011-Vaccine
TL;DR: Although there was no overall increase in intussusception following receipt of rotavirus vaccine, there was some evidence of an elevated risk following the first dose of both vaccines.

Journal ArticleDOI
18 Jul 2011-Vaccine
TL;DR: VAX102 was safe and induced high antibody levels to M2e at 0.3 and 1.0 μg doses and was able to induce a fourfold rise in antibody in humans, to a previously non-immunogenic, highly-conserved portion of the influenza virus.

Journal ArticleDOI
23 Sep 2011-Vaccine
TL;DR: This review summarises recent developments in the understanding of d Dengue pathogenesis and their relevance to dengue vaccine development.

Journal ArticleDOI
26 Aug 2011-Vaccine
TL;DR: The relative importance of specific CFs in achieving target product profiles for a future ETEC vaccine is demonstrated, however, heterogeneity across time, population, and region, confounded by variability in CF and toxin detection methodologies, obfuscates rational estimates for valency requirements.

Journal ArticleDOI
26 Oct 2011-Vaccine
TL;DR: A new 30-valent vaccine containing M protein peptides from GAS serotypes prevalent in North America and Europe was immunogenic in rabbits and evoked bactericidal antibodies against all 30 vaccine serotypes of GAS.

Journal ArticleDOI
26 Oct 2011-Vaccine
TL;DR: No statistically significant increased risk for any of the pre-specified adverse events after vaccination was detected in a study of over 600,000 HPV4 vaccine doses administered.

Journal ArticleDOI
08 Nov 2011-Vaccine
TL;DR: The role of each of the above mentioned carbohydrate antIGens in cancer growth and metastasis and vaccine attempts using these antigens will be described.

Journal ArticleDOI
15 Nov 2011-Vaccine
TL;DR: IPD due to PCV13-only serotypes halved in children under 2 years in the study period, and vaccine effectiveness (VE) for the new serotypes was 78% and 77% respectively although confidence intervals spanned zero.

Journal ArticleDOI
03 Nov 2011-Vaccine
TL;DR: Findings suggest missed clinical opportunities for HPV vaccination, and perceived barriers to vaccination may drive decisions about recommendation, and the need for age and specialty targeted practice and policy level interventions to increase HPV vaccination among US females.

Journal ArticleDOI
26 Oct 2011-Vaccine
TL;DR: There are enormous gaps in the understanding of porcine immunological mechanisms and processes that provide immunity to PRRSV infection and memory responses for long-term protection, and the authors should be confident that progress will be made.

Journal ArticleDOI
26 Oct 2011-Vaccine
TL;DR: HPV vaccination of 12-year-old males might potentially be cost-effective, particularly if female HPV vaccination coverage is low and if all potential health benefits of HPV vaccination are included in the analysis.

Journal ArticleDOI
22 Sep 2011-Vaccine
TL;DR: It is suggested that immunization with PCV13 has the potential to induce cross-protective responses to related serotypes not directly covered by the vaccine.

Journal ArticleDOI
30 Dec 2011-Vaccine
TL;DR: Since 1970, extensive epidemiology, virology, ecology and public health research has enabled better characterization of monkeypox virus and the associated human disease, and this work reviews the progress in this body of research.

Journal ArticleDOI
21 Mar 2011-Vaccine
TL;DR: Text message reminders were an effective intervention to increase on-time receipt of HPV2 or HPV3 in parents of adolescents 9-20 years who received HPV1 or HPV2 during the intervention period, January-June 2009.

Journal ArticleDOI
20 Jun 2011-Vaccine
TL;DR: Experimental immunisation of pigs with the non-virulent OURT88/3 genotype I isolate from Portugal followed by the closely related virulent OURt88/1 genotypes from Africa could confer protection against challenge with virulent isolates from Africa.

Journal ArticleDOI
24 Feb 2011-Vaccine
TL;DR: Anti-vaccination websites are constantly changing in response to the trends in public health and the success of vaccination, and effective vaccine support may be better served by including more emotionally compelling content.

Journal ArticleDOI
05 Aug 2011-Vaccine
TL;DR: Results indicate that vaccination with outer membrane vesicles may be a viable strategy for preventing A. baumannii infection.

Journal ArticleDOI
21 Nov 2011-Vaccine
TL;DR: It is demonstrated that the mode of secretion and trafficking can influence the immunogenicity of different human TAAs, and may explain the lack of immunogenicicity of non-mutated TAAs found in cancer patients, and suggested that exosomal targeting could enhance future anti-tumor vaccination protocols.

Journal ArticleDOI
18 Jul 2011-Vaccine
TL;DR: A(H1N1) vaccination is strongly associated with age, urbanicity, perceiving the A( H1N 1) vaccine as safe and seasonal flu vaccine uptake and perceptions of safety and season flu vaccination show the strongest associations with A(H 1N1)-related beliefs and seasonal vaccination.